Give Kids a Chance Act of 2024

HR 3433, the "Give Kids a Chance Act of 2024," requires pharmaceutical companies developing certain cancer drugs to conduct pediatric studies if the drugs target molecular pathways relevant to childhood cancers. It directly affects drug manufacturers submitting new applications for cancer treatments, particularly those combining previously approved adult cancer drugs or containing a single new active ingredient. The bill amends FDA regulations to mandate these pediatric investigations only when specific conditions are met, such as when a drug's molecular target is relevant to pediatric cancer growth. The FDA must issue implementing guidance within 12 months, and reports to Congress will track implementation and effectiveness starting 2 years after enactment.